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ABSTRACT: The 1988 Amendments to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) accelerated the 
reregistration schedule for pesticide products registered with the Environmental Protection Agency (EPA) prior to 1984. The 
compound 3-chloro-p-toluidine hydrochloride (DRC-1339), an avicide registered to control 14 pest bird species, was included 
on Pesticide List B published by EPA. For the reregistration of DRC-1339,44 studies were required — 22 product chemistry, 
7 wildlife/aquatic hazards, 8 human/domestic animal hazards, 5 environmental fate, and 2 residue chemistry studies. In 5 acute 
human-health-hazards studies, DRC-1339 was found to: (1) have an oral LD50 of 330 (272-401) mg/kg in rats, (2) have a 
dermal LD50 of >2.0 g/kg in rabbits, (3) cause corrosive effects to the eyes of rabbits, (4) cause corrosive effects to the skin of 
rabbits, and (5) induce dermal sensitization in guinea pigs. Results support the current precautionary statements on the “use 
labels” warning of harmful ingestion, inhalation, dermal absorption and eye irritation effects to users of the active ingredient. 
Proc. 15th Vertebrate Pest Conf. (J. E. Borrecco & R. E. Marsh, 
Editors) Published at University of Calif., Davis.  1992 
INTRODUCTION 
The chemical 3-chloro-p-toluidine hydrochloride 
(C7H9NCl2; DRC-1339) is an effective avicide that is used in 
a pelleted bait marketed under the tradename Starlicide 
Complete® by Purina Mills, Inc., St. Louis, MO (Besser et al. 
1967, Decino et al. 1966, Schafer 1981). Because DRC-1339 
is highly toxic (LD50<10 mg/kg) to most passerines, 
columbids, and corvids but only moderately toxic (LD50 > 100 
mg/kg) to most raptors and mammals, the chemical is consid-
ered selective for target species. Risks of primary or second-
ary hazards to non-target animals are low (Cunningham et al. 
1981; Savarie and Schafer 1986, Schafer 1984). 
The reregistration of DRC-1339 is a priority of the U. S. 
Department of Agriculture (USDA), Animal and Plant Health 
Inspection Service (APHIS), Animal Damage Control (ADC) 
Program (Knittle et al. 1990). Purina Mills, Inc. and APHIS 
currently have 2 Federal (FIFRA Section 3) and 28 State 
(FIFRA Section 24C) registrations for the compound. These 
cover 6 general applications, including pigeons on/near urban 
structures or rural non-crop areas, gulls on/near coastal is-
lands, blackbirds foraging on grain at livestock feedlots, 
blackbirds at large roost-staging areas, corvids depredating 
on newborn calves/lambs, and corvids foraging on endan-
gered/threatened species. Altogether, 14 target species are 
cited on the “use labels”; these include: pigeon (Columba 
livid), herring gull (Larus argentatus), great black-backed gull 
(Lams marinus), ring-billed gull (Larus delawarensis), com-
mon raven (Corvus corax), common crow (Corvus brachyn-
chos), Brewer's blackbird (Euphagus cyanocephalus), 
brownheaded cowbird (Molothrus ater), common grackle 
(Quisculus quiscula), great-tailed grackle (Cassidix mexi-
canus), red-winged blackbird (Agelaius phoeniceus), starling 
(Sturnus vulgaris), tricolored blackbird (Agelaius tricolor), 
and blackbilled magpie (Pica pica). 
This paper presents: (1) an overview of the FIFRA-1988 
Process which directed the 9-year, 5-phase reregistration 
schedule for pesticide products, (2) a description of the Code 
of Federal Regulations (CFR) 40 (Parts 150-189) which es-
tablished basic procedures for the conduct of pesticide tests 
(EPA 1991), and (3) a summary of 5 acute human-health-
hazards studies submitted to the EPA in support of DRC-
1339 reregistration. 
THE FIFRA-1988 PROCESS 
DRC-1339 was originally registered in 1967 (Knittle et 
al. 1990). Only minimal environmental safety and human 
health hazards data were required at that time. The 1972 
amendments to FIFRA, titled the Federal Environmental 
Control Pesticide Act, mandated that all pesticides must meet 
registration data requirements (be reregistered) within a 5-
year period (Fagerstone et al. 1990). EPA was directed to 
reevaluate the environmental safety/human hazards associ-
ated with about 600 active ingredients and 45,000 formulated 
products. Because of the magnitude of this task, progress by 
EPA was slow. In 1988, Congress amended FIFRA to accel-
erate EPA's reregistration efforts. FIFRA-1988 required that 
all pesticides containing an active ingredient first registered 
prior to November 1,1984 must be reregistered within a 9-
year period in 5 phases. 
Phase 1 
In Phase 1 EPA issued 4 lists (A, B, C, D) of active 
ingredients (A.I.) subject to reregistration. List A contained 
194 groups of related pesticide active ingredients (350 spe-
cific A.I.) for which EPA had issued Registration Standards 
before the effective date of FIFRA-1988. Remaining pesti-
cides were divided into 3 lists (Lists B—229 A.I., C—288 
A.I., and D—286 A.I.) based upon their potential for human 
exposure and environmental risks. DRC-1339 appeared on 
List B dated May 25,1989. 
Phase 2 
This phase gave registrants 90 days to notify EPA 
whether or not they intended to reregister their active ingredi-
ents, to commit to providing necessary new studies, and to 
pay newly imposed reregistration and maintenance fees 
(Fagerstone 1990). Because the low-volume use of DRC-
1339 technical product (< 100 lbs./year) made it economically 
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infeasible for Purina Mills, Inc. (the technical registrant) to 
maintain the technical product registration, USDA/APHIS 
formed an informal consortium with Purina to reregister 
DRC-1339. Purina and USDA/APHIS mutually projected a 
continued need for the compound as an agricultural avicide 
and agreed to provide 22 product chemistry, 7 wildlife/aquatic 
hazards, 8 human/domestic animal hazards, 5 environmental 
fate, and 2 residue studies required to reregister the DRC-
1339 A.I. 
Phase 3 
Phase 3 required registrants to provide summaries of 
existing studies that might be used to support reregistration, 
to initiate new studies, and to identify known adverse effects. 
For DRC-1339, no summaries of prior studies were submit-
ted, but 44 new studies were initiated in Phase 2. To date, 39 
of these studies have been completed and submitted to EPA. 
Phase 4 
During this Phase, EPA reviewed the data submitted. A 
Data Call-In was received from EPA on February 25, 1991 
identifying 13 additional studies of which 6 were ultimately 
required (3 Product Chemistry, 1 Human/Domestic Animal 
Hazards, and 2 Environmental Fate studies). These are in-
cluded in the total studies cited under Phase 3. 
Phase 5 
In Phase 5 EPA will review all the submitted studies and 
decide whether or not to reregister the active ingredient — 
issue/not issue a "Registration Eligibility Document (RED)." 
The EPA will also identify specific studies that will be needed 
for reregistration of end-use products (the field formulations). 
DATA REQUIREMENTS 
40 CFR (Parts 150-189) specifies the types of chemical/ 
environmental/ human health hazards studies required for 
pesticide registration or reregistration (EPA 1991). It also 
defines technical terms and outlines Good Laboratory Prac-
tice (GLP) standards to be used in data collections. Twelve 
“Subdivisions” to the Code specify the types of data to be 
provided by the registrants) for an active ingredient (see 
Figure 1). Each of these Subdivisions contains a matrix of the 
studies required for the chemical's “general use pattern” (ter-
restrial: food/non-food crop; aquatic: food/non-food crop; 
greenhouse: food/non-food crop; forestry; domestic outdoor; 
and indoor) and “test substance” (manufacturing-use product 
or end-use product). 
The specific studies that compose Subdivision F (Haz-
ards Evaluation: Human and Domestic Animals) are included 
under 5 categories: Acute, Subchronic, Chronic, Mutagenic-
ity, and Special Testing. In this paper, we present a summary 
of 5 recently completed Acute Tests for DRC-1339: (1) 
Acute Oral Toxicity—Rat (GRN 81-1), (2) Acute Dermal 
Toxicity—Rabbit (GRN 81-2), (3) Primary Eye Irritation— 
Rabbit (GRN 81-4), (4) Primary Dermal Irritation—Rabbit 
(GRN 81-5), and (5) Dermal Sensitization—Guinea Pig 
(GRN 81-6) (see Fig. 1). 
ACUTE HUMAN-HEALTH-HAZARDS 
STUDIES FOR DRC-1339 
Based on negotiations between EPA, Purina Mills, Inc., 
and USDA/APHIS, the following 5 acute, human health haz- 
 
Figure l. The 12 Subdivisions of tests presented in 40 CFR that 
may be required to register/reregister a pesticide (top); and, the 
acute data required for reregistration of DRC-1339 (Subdivi-
sion F-Hazard Evaluation: Humans and Domestic Animals) 
under Phases 2 and 3 of FIFRA-1988 (see EPA 1991). 
ards studies were required for reregistration of DRC-1339. 
These studies were contracted to MB Research Laboratories, 
Inc., Spinnerstown, PA. All studies adhered to Good Labora-
tory Practice provisions as specified in 40 CFR Part 160. Data 
from these studies could impact the wording of precautionary 
statements to human users of DRC-1339 included on the 
pesticide “use labels.” 
Acute Oral Toxicity—Rat 
(Single Oral Dose LD50) (GRN 81-1) 
Objective—This test was conducted to determine the 
acute toxicity of DRC-1339 when administered via gavage as 
a single oral dose to male and female albino rats (Rattus 
norvegicus). 
Methods—Following a quarantine period of at least 1 
week, 5 healthy male and 5 female Wistar albino rats (each 
approximately 8 weeks old and weighing between 200-300 
g) were randomly assigned to each of 5 dose groups (247, 
312, 500, and 1000 mg/kg); an additional group of 5 female 
rats was tested at 277 mg/kg to further clarify the dose re- 
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sponse function for that gender. The pre-test weight range 
was 204-300 g for males and 212-253 g for females. The 
weight variation of the animals did not exceed ±20% of the 
mean weight. Rats were identified by cage notation and in-
delible body marks, and were housed 1/cage in suspended 
wire mesh cages. Bedding was placed beneath the cages and 
changed twice/week. Fresh Purina Rat Chow Diet #50121 
(Purina Mills, Inc., St. Louis, MO) was provided ad libitum, 
except for 16-20 h prior to dosing (fasted). Water was avail-
able ad libitum. 
The animal room (reserved exclusively for rats on acute 
tests) was temperature controlled (19-21° C), with a 12:12 h 
light:dark (0600-1800 and 1800-0600 h) schedule. The test 
substance (97.1% DRC-1339) was used as a 25% w/v dilu-
tion in distilled water for each dose level. 
Each rat received the respective oral dose via gavage. 
The rats were observed 1, 2, and 4 h post dose, and once daily 
thereafter for 14 successive days to determine toxicity and 
pharmacological effects. Each animal was observed twice 
daily for mortality. Body weights were recorded immediately 
pretest, weekly, and at death or study termination (survivors). 
All animals were necropsied for gross pathology. 
Results—Mortality (male:female) to the 5 doses was: 
247 mg/kg (1:1), 277 (no males tested:l), 312 mg/kg (0:5), 
500 mg/kg (4:5), and 1000 mg/kg (5:5). Deaths occurred by 
Day 6 and were preceded by physical signs of lethargy, ataxia 
(uncoordinated movements), muscle flaccidity, negative 
righting reflex, chromodacryorrhea (reddish ocular dis-
charge), ptosis (partial eyelid closure with constricted pupil), 
piloerection, tachypnea (increased respiration rate), 
chromorhinorrhea (colored discharge from nose), coma, 
prostration, brown staining of bodily areas, and wetness of 
the nose/mouth area. Necropsy of the dead rats revealed ab-
normalities of the lungs, liver, kidneys, urinary bladder, heart, 
and gastrointestinal tract, as well as wetness and brown stain-
ing of the nose/mouth and anogenital areas. 
Physical signs noted in survivors included: lethargy, 
ataxia, piloerection, muscle flaccidity, tachypnea, 
chromorhinorrhea, and wetness or brown staining of the nose/ 
mouth area. Body weight effects were minimal, however, 
instances of weight loss or less than normal weight gain were 
noted for several rats. The LD50 values (95% confidence in-
tervals) were: males—350 (267-458) mg/kg, females — 303 
(263-349) mg/kg, and males/females combined — 330 (272-
401) mg/kg of body weight (Litchfield and Wilcoxon 1949). 
According to EPA toxicology criteria, DRC-1339 is a 
Category II Toxicant (LD50 >50 but <500 mg/kg). 
Acute Dermal Toxicity (LD50)—Rabbit (GRN 81-2) 
Objective—This test was conducted to determine the 
potential toxicity of DRC-1339 when applied dermally and 
kept in contact with the skin of rabbits for 24 h. 
Methods—Following a quarantine period of at least 1 
week, 5 healthy male and 5 healthy female New Zealand 
albino rabbits (Oryctolagus cuniculus) were randomly selec-
ted for test. The minimum and maximum pretest weights of 
the rabbits were 2.3 to 2.4 kg (males) and 2.1 to 2.5 kg 
(females). Animals were identified by cage notation and 
uniquely numbered metal ear tags; they were housed 1/cage 
1Reference to trade names does not imply endorsement by the 
U.S. Government. 
in suspended wire mesh cages. The rabbits were provided 
fresh Purina Rabbit Chow Diet #5321 (Purina Mills, Inc., St. 
Louis, MO) and water ad libitum. The animal room (reserved 
exclusively for rabbits on acute tests) was temperature con-
trolled (19-21° C); a 12:12 h light:dark schedule (0600-1800 
and 1800-0600 h) was used. Approximately 24 h before ap-
plication of the test substance (97.1% DRC-1339), a large 
(10% of body surface) dorsal spot on the back of each rabbit 
was shaved; the skin of each animal was checked and found 
to be intact (unbroken) prior to test. 
The DRC-1339 was moistened (made pasty) with dis-
tilled water, and applied onto the shaved dermal site, 1 time, 
via syringe-type applicator. The dose was 2.0 g/kg of body 
weight based upon the weight of the dry DRC-1339. The site 
was then covered with a gauze patch, secured with non-irri-
tating tape (gentle pressure was applied to the gauze to dis-
tribute the product over the covered site). The torso was then 
wrapped with thin plastic to prevent rubbing/scratching of the 
treated area and secured with non-irritating tape. At 24 h, the 
patch was removed, and the residual DRC-1339 was washed 
off the skin with water. Test sites for each rabbit were scored 
for dermal irritation at 24 h post dose and on Days 7 and 14 
using the Draize Dermal Scale (Draize 1944). Additional 
toxic signs were also described. 
Regarding general toxicity and pharmacological signs, 
the rabbits were observed at 1, 2, and 4 h post dose and once 
daily throughout the 14-day test. Each rabbit was observed 
twice daily for mortality during this period. Body weights 
were recorded pretest, weekly, and at termination of the test. 
All rabbits were necropsied and examined for gross pathol-
ogy upon completion of Day 14. 
Results—All rabbits survived the 2.0 g/kg dermal ap-
plication. Physical signs of diarrhea, few feces, and soiling of 
the anogenital area were noted in some animals. 
No rabbits showed changes in body weights. Dermal 
reactions, slight to well-defined on Day 1, were absent to 
severe by Day 14 (considerable variability observed). The 
treated skin of all rabbits was stained orange at 24 h. Slight to 
well-defined erythema (redness) was observed for 6 of 10 
rabbits at 24 h, with 3 males eventually scored as severe by 
Day 7; whereas, 2 males continued to be scored as having 
severe erythema at Day 14. Edema (fluid production/drain-
age) was observed on all rabbits at 24 h, but then decreased to 
slight edema on 4 rabbits at Day 7; no animals showed edema 
on Day 14. Additional signs that were evident for at least a 
portion of the rabbits were most frequent on Day 7 and in-
cluded: orange skin, flaking skin, and shiny areas. Necropsies 
revealed abnormalities of the treated skin, liver, kidneys, in-
testines, and urinary bladder; data for 1 rabbit (male) ap-
peared “normal.” 
The LD50 was determined to be >2.0 g/kg of body weight 
—no deaths recorded. Thus, DRC-1339 is classed as a Cat-
egory III Toxicant for dermal effects—>2000 mg/kg. 
Primary Eye Irritation—Rabbit (GRN 81-4) 
Objective—The objective was to determine the irrita-
tion/corrosive effects of DRC-1339 when instilled into the 
eyes of rabbits. This is a derivation of the well-known “Draize 
Test” (Draize et al. 1944). 
Methods—Following quarantine of at least 1 week, 6 
healthy New Zealand albino rabbits (free from ocular irrita-
tion) were designated for test. Minimum and maximum pre- 
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test body weights of the rabbits were 2.3 and 2.5 kg, respec-
tively. The rabbits were identified by cage notation and a 
uniquely numbered metal ear tag. Rabbits were housed 1/ 
cage in suspended wire mesh cages located within a tempera-
ture-controlled (19-21° C) animal room that was reserved 
exclusively for rabbits on acute tests with a 12:12 h (0600-
1800 and 1800-0600 h) light:dark schedule in effect. Fresh 
Purina Rabbit Chow Diet #5321 (Purina Mills, Inc., St. Louis, 
MO) and water were provided ad libitum. 
Approximately a 0.1 ml equivalent (mean of 54 mg) of 
dry DRC-1339 (97.1%) was placed into the conjunctival sac 
of 1 eye of each rabbit; the contralateral eye served as a 
control. After instillation, the eyelids were held together for 
approximately 1 sec; the eyes were not washed. Ocular re-
sponses were graded according to the Draize Scale (i.e., 
maximum scores of 80, 10 and 20 were possible for cornea, 
iris, and conjunctivae, respectively); these were recorded at 1 
h post instillation and on Days 1, 2, 3, and 7 of a scheduled 
21-day test (Draize 1944). The eyes of each rabbit were ex-
amined using sodium fluorescein for the Day-1 grading of 
corneal effects; sodium fluorescein penetrates corneal distur-
bances and shows the area of ocular effect during the early 
observations. Reversible change to the eye was considered 
evidence of irritation; irreversible tissue damage to the ante-
rior surface of the eye was considered evidence of corrosion. 
Results—Corneal opacity, iritis, and severe conjuncti-
val irritation were noted in the test eyes of all 6 rabbits, and 
these symptoms persisted through Day 7. Due to the severity 
of the corneal, iris, and conjunctival reactions (corrosive ef-
fects) in all of the rabbits, the study was terminated on Day 8 
of the test for “humaneness reasons.” An expert veterinary 
ophthalmologist inspected the animals and prepared a de-
tailed report to justify early termination. Diarrhea was the 
only abnormal systemic sign noted during the observation 
period. 
The test substance (DRC-1339) is considered to be a 
Category I Toxicant—corrosive (irreversible destruction of 
ocular tissues) or corneal involvement or irritation persisting 
for more than 21 days. 
Primary Dermal Irritation—Rabbits (GRN 81-5) 
Objective—This test was conducted to determine the 
irritant or corrosive effects of DRC-1339 when applied 
dermally and kept in contact with the skin of rabbits for 4 h. 
Methods—Following at least 1 week of quarantine, 6 
healthy New Zealand albino rabbits (approximately 8 weeks 
old) were selected for this test. Pretest body weights of the 
rabbits were between 2.1 and 2.4 kg. The rabbits were identi-
fied by cage notation and uniquely numbered metal ear tags. 
Animals were housed I/cage in suspended wire mesh cages 
located in a room reserved exclusively for rabbits on acute 
tests. This room was temperature-controlled (19-21° C), with 
a 12:12 h light:dark (0600-1800 and 1800-0600 h) schedule. 
Body weights of each rabbit were recorded pretest. 
Approximately 24 h prior to the application of DRC-
1339, about a 10 cm2 area on the dorsal trunk of each animal 
was shaved; the site remained intact (unbroken) for all ani-
mals. On Day 1, 0.5 g of DRC-1339 (moistened with distilled 
water to form a paste) was placed on the treated site of each 
animal for 4 h. A gauze patch was place over the paste and 
secured with non-irritating adhesive tape; the torso of the 
rabbit was then wrapped with a semi-occlusive dressing and 
secured with adhesive tape to retard evaporation of volatile 
substances. At the end of 4 h, the wrappings and gauze were 
removed, and the site was washed gently with water to re-
move residual DRC-1339. 
Rabbits were observed for skin reactions at 30 and 60 
min after removal of the site coverings and at 24, 48, and 72 h 
post removal. Erythema and edema were scored according to 
the Draize Dermal Technique (Draize et. al. 1944). Dermal 
irritation was defined as the production of reversible inflam-
matory changes to the skin; dermal corrosion referred to irre-
versible tissue damage to the skin. Ulceration, necrosis, and 
possible tissue destruction were also observed. To determine 
reversibility of DRC-1339 produced skin effects, measure-
ments were made on Days 7 and 14. 
Results—Dermal scores were variable for the 6 rabbits. 
Erythema scores ranged from slight to moderate at 1 and 24 h 
post patch removal and slight to severe at 48 and 72 h post 
removal. Erythema remained slight to severe on Days 7 and 
14. Edema was slight to moderate at 1 h post patch removal 
but absent to well-defined throughout the remainder of the 
test. Instances of moderate eschar (black areas and areas of 
shiny skin indicative of injuries in depth) were noted during 
the test. Instances of diarrhea for certain rabbits were the only 
abnormal systemic signs noted. 
Based on the observed “injuries in depth” (eschar) to 
some rabbits, DRC-1339 is judged to be a Category I Toxi-
cant for dermal effects following 4 h of contact — corrosive 
(tissue destruction into the dermis or scarring for some ani-
mals). 
Dermal Sensitization — Guinea Pig (GRN 81-6) 
Objective—The objective of this test was to determine 
the potential of DRC-1339 to promote skin sensitization reac-
tions after repeated topical “skin insult” applications in guinea 
pigs. 
Methods—Following quarantine of at least 5 days, 34 
healthy male Hartley albino guinea pigs (Cavia cobaya) were 
selected for the test. Pretest body weights of the animals were 
between 355 and 400 g. Each guinea pig was identified by 
specific cage notation and a uniquely numbered ear tag. The 
animals were housed 1/cage in suspended rodent-type cages. 
Fresh Purina Guinea Pig Chow Diet #5025 (Purina Mills, 
Inc., St. Louis, MO) and water were available ad libitum. The 
animals were maintained in a temperature-controlled (19-21° 
C), light-/dark-controlled (0600-1800 and 1800-0600 h) room 
that was reserved exclusively for guinea pigs on acute tests. 
The test procedure used the Buehler Method. Prior to 
initiation of the study, a topical preliminary screen was con-
ducted using 4 guinea pigs. This was to determine a “mildly 
irritating” and a “highest non-irritating” concentration of 
DRC-1339. A dorsal area of about 5 by 10 cm on each animal 
was clipped free of hair 24 h prior to test (skin unbroken). 
Eight concentrations of DRC-1339 (0.1, 0.5, 1, 5, 10, 25, 50, 
and 100%) were prepared using distilled water; the 100% 
concentration was prepared by mixing the dry chemical with 
a few drops of distilled water. Each animal received 4 con-
centrations of DRC-1339 (i.e., 1 at each of 4 sites/guinea pig). 
Except for the 100% concentration, which was applied as a 
paste and covered with a gauze patch, the concentrations 
were placed onto the skin and covered with a 25-mm Hilltop 
Chamber (a clear plastic cover). Finally, the sites were cov-
ered with a rubber dental dam large enough to span the 4 
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sites. Two pieces of elastoplast tape were used to cover the 
dam. The DRC-1339 remained in place for 6 h. Then, the 
tape, dam, chambers, and gauze were removed; residual 
DRC-1339 was washed away with distilled water and the 
sites dried using soft toweling. The treated sites were exam-
ined and scored at 24 and 48 h post application using the 
Draize Dermal Scoring Technique (Draize et al. 1944). Based 
on irritation scores, the “mildly irritating concentration” cho-
sen for the sensitization study was the 100% dose and the 
“highest non-irritating concentration” was the 25% dose. 
The main sensitization study involved 30 guinea pigs 
assigned to 4 groups; these animals were housed, treated, and 
prepared essentially the same as those in the preliminary 
screen. The total study involved a 38-day sequence consisting 
of a 21-day induction phase, a 14-day waiting phase, and a 3-
day challenge phase. Group 1 (n=10) received 3 topical in-
ductions over a 3 week period of the “mildly irritating” 
(100%) concentration. Group 2 (n=5) served as the non-in-
duced control for DRC-1339; this Group would be tested 
during the challenge phase only. Group 3 (n=10) served as a 
“positive control”; this group was dosed with a 0.2% concen-
tration of Dinitrochlorobenzene (DNCB) in the same manner 
as the DRC-1339 animals—DNCB is a known dermal 
senitizer. Finally, Group 4 (n=5) served as the non-induced 
control for DNCB; this Group received applications of DNCB 
only during the challenge phase. Skin reactions of guinea 
pigs in Groups 1 and 3 were recorded at 24 and 48 h after 
induction. 
Two weeks after the third induction with DRC-1339 or 
DNCB, Groups 1 and 2 were challenged with a 25% concen-
tration of DRC-1339, and Groups 3 and 4 were challenged 
with a 0.1% concentration of DNCB. Skin reactions of the 
guinea pigs in each of the 4 groups were scored at 24, 48, and 
72 h post challenge application. 
Results—Erythema of the dermal sites was absent to 
mild following Induction 1, mild to severe following Induc-
tion 2, and absent to mild following Induction 3. Edema was 
absent to mild following Induction 1, slight to mild following 
Induction 2, and absent to barely perceptible following 
Induction 3. 
During the challenge phase, positive responses were 
noted in 7 of 10 DRC-1339-treated guinea pigs and 6 of 10 
DNCB controls. Erythema ranged from barely perceptible 
to mild at 24 h, absent to slight at 48 h, and absent to very 
slight at 72 h for DRC-1339 animals. Edema, absent at 24 h, 
was absent to slight in select animals by 48 h post challenge, 
and absent to very slight at 72 h post challenge. There were 
no positive responses to the challenge concentrations (25% 
DRC-1339 or 0.1% DNCB) in the non-induced control 
guinea pigs. 
Due to the frequencies and severities of reactions during 
the challenge phase, both DRC-1339 and DNCB are consid-
ered “dermal sensitizers.” 
CONCLUSIONS 
Reregistration of DRC-1339 is progressing on schedule; 
the 44 studies required to address potential adverse environ-
mental/human-health effects will be completed in 1994. Re-
sults from the 5 acute studies conducted to provide data for 
Subdivision F (40 CFR Part 158.34) Requirements showed 
that DRC-1339: (1) has an oral LD50 of 330 (272-401) mg/kg 
in rats, (2) has a dermal LD50 of >2.0 g/kg in rabbits, (3) 
causes corrosive effects to the eyes of rabbits, (4) causes 
corrosive effects to the skin of rabbits, and (5) induces dermal 
sensitization in guinea pigs. The “precautionary statements” 
for DRC-1339 contained in the upper left portion of pesticide 
“use labels” currently read: 
Harmful if swallowed, inhaled, or absorbed through 
the skin. Avoid contact with eyes, skin, or clothing. 
Handle only with protective gloves, clothing, and face 
mask, or respirator. Wash hands with soap and water 
after handling. 
These precautions concur with the previously described 
results. 
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